Expanded access to MTP-PE for osteosarcoma
Part of Cancer clinical trials.
This trial provides access to a drug called MTP-PE for people with osteosarcoma, a type of bone cancer. It is for patients who have had surgery or other treatment to remove all visible cancer and who may benefit from this drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have osteosarcoma, either newly diagnosed or returned after treatment.
- All visible cancer must have been removed with surgery or another local treatment.
- You must be expected to live at least 6 more weeks.
- Your bone marrow, kidneys, and liver must be working well enough.
- If you are sexually active, you must agree to use barrier contraception during and for 1 year after the study.
- You must not be taking long-term steroids or other drugs that weaken the immune system, and you cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines four targeted drugs (gefitinib, trametinib, disulfiram, sunitinib) with standard chemotherapy to treat osteosarcoma that has spread or come back. The goal is to see if this drug mix helps shrink tumors or keep them from growing.
This trial tests a new drug called OMO-103, which targets a protein called Myc that helps cancer cells grow. It is for people with advanced osteosarcoma (bone cancer) that has worsened after standard chemotherapy. The drug is given intravenously (through a vein), and the study will check if it is safe and shrinks tumors.
This study tests whether the combination of two drugs, apatinib (a targeted therapy) and liposomal irinotecan (a chemotherapy), can help people with osteosarcoma that has not responded to standard treatments or has spread. The goal is to see if the combination can shrink tumors or slow the disease.
This Phase 2 trial studies HS-20093 in adults with osteosarcoma or other sarcomas that came back or did not respond to standard treatment. It aims to see how well the drug works and whether it is safe for people whose cancer has progressed.
This study tests two treatments for high-risk osteosarcoma (a bone cancer). It compares mifamurtide plus standard treatment versus sorafenib plus standard treatment to see which is safer and more effective.
This trial tests a combination of immunotherapy and targeted radiation before surgery for osteosarcoma that has spread to the lungs. It aims to see if this approach can help shrink or control the lung tumors and make surgery more effective.
Hear when a new Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.